MMP-9 Activation by Tumor Trypsin-2 Enhances in vivo Invasion of Human Tongue Carcinoma Cells

Abstract

Various human cancer cells express tumor-associated trypsinogen-2 (TAT-2), which can efficiently activate matrix metalloproteinases (MMPs) in vitro. MMP-2 and MMP-9 are particularly associated with the invasive malignant potential of several tumors. To investigate the role of TAT-2 in tumor invasion, we overexpressed TAT-2 in two malignant human squamous cell carcinoma cell lines of tongue and in non-malignant human papilloma virus transformed gingival keratinocytes. The TAT-2 overexpression significantly increased the levels of active MMP-9 in the most malignant cell line. TAT-2-transfected cells intravasated (invaded blood vessels) up to 60% more efficiently than did the control cells in an in vivo chick embryo chorioallantoic membrane invasion model. This increased intravasation was almost completely abolished by a specific tumor-associated trypsin inhibitor (TATI). These results indicate that TAT-2 has a role in the invasive growth of tumors, either alone or in cascade with gelatinases, especially by generating active MMP-9.

Get full access to this article

View all access options for this article.

References

Chambers AF, Matrisian LM -1997-. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 87:1260–1270.

Dionisi HM, Checa SK, Viale AM -1995-. Protein immunoblotting of stained gels. Biotechniques 19:348–350.

Duncan ME, Richardson JP, Murray GI, Melvin WT, Fothergill JE -1998-. Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form. Eur J Biochem 258:37–43.

Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, et al. -1986-. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 41:305–310.

Halila H, Lehtovirta P, Stenman UH -1988-. Tumour-associated trypsin inhibitor -TATI- in ovarian cancer. Br J Cancer 57:304–307.

Itkonen O, Koivunen E, Hurme M, Alfthan H, Schroder T, Stenman UH -1990-. Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitis. J Lab Clin Med 115:712–718.

Juarez J, Clayman G, Nakajima M, Tanabe KK, Saya H, Nicolson GL, et al. -1993-. Role and regulation of expression of 92-kDa type-IV collagenase -MMP-9- in invasive squamous-cell-carcinoma cell lines of the oral cavity. Int J Cancer 55:10–18.

Kato Y, Nagashima Y, Koshikawa N, Miyagi Y, Yasumitsu H, Miyazaki K -1998-. Production of trypsins by human gastric cancer cells correlates with their malignant phenotype. Eur J Cancer 34:1117–1123.

Kawamata H, Uchida D, Hamano H, Kimura-Yanagawa T, Nakashiro KI, Hino S, et al. -1998-. Active MMP-2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis. Int J Oncol 13:699–704.

10.

Kim J, Yu W, Kovalski K, Ossowski L -1998-. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay. Cell 94:353–362.

11.

Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N -1993-. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 268:10425–10432.

12.

Koivunen E, Itkonen O, Halila H, Stenman UH -1990-. Cyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2. Cancer Res 50:2375–2378.

13.

Koivunen E, Ristimäki A, Itkonen O, Osman S, Vuento M, Stenman UH -1991-. Tumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrix. Cancer Res 51:2107–2112.

14.

Koivunen E, Arap W, Valtanen H, Raininsalo A, Medina OP, Heikkilä P, et al. -1999-. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17:768–774.

15.

Lukkonen A, Sorsa T, Salo T, Tervahartiala T, Koivunen E, Golub L, et al. -2000-. Down-regulation of trypsinogen-2 expression by chemically modified tetracyclines: association with reduced cancer cell migration. Int J Cancer 86:577–581.

16.

Mignatti P, Rifkin DB -1993-. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73:161–195.

17.

Miyata S, Miyagi Y, Koshikawa N, Nagashima Y, Kato Y, Yasumitsu H, et al. -1998-. Stimulation of cellular growth and adhesion to fibronectin and vitronectin in culture and tumorigenicity in nude mice by overexpression of trypsinogen in human gastric cancer cells. Clin Exp Metastasis 16:613–622.

18.

Oda D, Bigler L, Lee P, Blanton R -1996-. HPV immortalization of human oral epithelial cells: a model for carcinogenesis. Exp Cell Res 226:164–169.

19.

O'Grady RL, Nethery A, Hunter N -1984-. A fluorescent screening assay for collagenase using collagen labeled with 2-methoxy-2,4-diphenyl-3-²H--furanone. Anal Biochem 140:490–494.

20.

Osman S, Turpeinen U, Itkonen O, Stenman UH -1993-. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor -TATI- using the streptavidin-biotin system. J Immunol Methods 161:97–106.

21.

Paju A, Sorsa T, Tervahartiala T, Koivunen E, Haglund C, Leminen A, et al. -2001-. The levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinases-9 but not promatrix metalloproteinases-2 activation. Br J Cancer 84:1363–1371.

22.

Ramos DM, Chen BL, Boylen K, Stern M, Kramer RH, Sheppard D, et al. -1997-. Stromal fibroblasts influence oral squamous-cell carcinoma cell interactions with tenascin-c. Int J Cancer 72:369–376.

23.

Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, et al. -1997-. Activation of type IV procollagenases by human tumor-associated trypsin-2. J Biol Chem 272:21067–21074.

24.

Tani T, Kawashima I, Mita K, Takiguchi Y -1990-. Nucleotide sequence of the human pancreatic trypsinogen III cDNA -abstract-. Nucleic Acids Res 18:1631.

25.

Wiegand U, Corbach S, Minn A, Kang J, Müller-Hill B -1993-. Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene 136:167–175.